OptiNose Inc (NASDAQ:OPTN) was the recipient of a significant increase in short interest during the month of July. As of July 15th, there was short interest totalling 8,656,800 shares, an increase of 7.6% from the June 15th total of 8,045,600 shares. Based on an average daily volume of 196,500 shares, the short-interest ratio is currently 44.1 days. Currently, 55.4% of the shares of the company are short sold.

Several hedge funds have recently added to or reduced their stakes in OPTN. BlackRock Inc. grew its stake in OptiNose by 69.0% during the fourth quarter. BlackRock Inc. now owns 1,820,167 shares of the company’s stock worth $11,285,000 after buying an additional 743,369 shares in the last quarter. Rice Hall James & Associates LLC raised its holdings in OptiNose by 32.9% in the 1st quarter. Rice Hall James & Associates LLC now owns 1,414,682 shares of the company’s stock valued at $14,571,000 after buying an additional 349,820 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in OptiNose by 8.1% in the 1st quarter. JPMorgan Chase & Co. now owns 2,503,969 shares of the company’s stock valued at $25,791,000 after buying an additional 187,174 shares during the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in OptiNose in the 4th quarter valued at approximately $1,108,000. Finally, Two Sigma Investments LP bought a new position in OptiNose in the 4th quarter valued at approximately $646,000. Institutional investors and hedge funds own 63.68% of the company’s stock.

Several equities analysts have commented on the stock. Piper Jaffray Companies set a $29.00 price objective on shares of OptiNose and gave the company a “buy” rating in a report on Tuesday, April 23rd. Zacks Investment Research upgraded shares of General Moly from a “sell” rating to a “hold” rating in a report on Thursday, July 11th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $27.00 price objective on shares of Spero Therapeutics in a report on Thursday, May 9th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. OptiNose presently has an average rating of “Buy” and a consensus price target of $23.30.

Shares of OPTN stock traded down $0.30 on Monday, hitting $5.69. The company’s stock had a trading volume of 120,412 shares, compared to its average volume of 174,602. The company has a debt-to-equity ratio of 0.79, a current ratio of 6.95 and a quick ratio of 6.74. The business has a 50 day simple moving average of $6.85. OptiNose has a fifty-two week low of $5.50 and a fifty-two week high of $22.96. The company has a market cap of $234.79 million, a P/E ratio of -2.12 and a beta of 0.93.

OptiNose (NASDAQ:OPTN) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.70) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.01. OptiNose had a negative net margin of 983.22% and a negative return on equity of 81.04%. The business had revenue of $4.48 million for the quarter, compared to the consensus estimate of $4.35 million. On average, sell-side analysts anticipate that OptiNose will post -2.97 earnings per share for the current year.

OptiNose Company Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.

Read More: What are economic reports?

Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.